Keywords
Levofloxacin
Elderly community-acquired pneumonia
Clinical efficacy
Submitted : 2024-12-03
Accepted : 2024-12-18
Published : 2025-01-02
Abstract
Objective: To compare the clinical efficacy of moxifloxacin and levofloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). Methods: A total of 80 elderly CAP patients admitted between April 2023 and February 2024 were randomly divided into two groups. The control group (n = 40) received treatment with levofloxacin, while the observation group (n = 40) was treated with moxifloxacin. Relevant clinical indicators were observed and compared between the two groups. Results: The overall effective treatment rate in the observation group reached 95.00%, significantly higher than the 75.00% observed in the control group (P < 0.05). The time required for improvement in clinical symptoms was significantly shorter in the observation group compared to the control group (P < 0.001). Pulmonary function indicators, including FVC, FEV1, and FEV1/FVC, improved in both groups after treatment, but the improvement was more pronounced in the observation group (P < 0.001). Serum inflammatory factor levels indicated that post-treatment levels of IL-6, PCT, and CRP decreased in both groups compared to pre-treatment levels, with a more significant reduction in the observation group (P < 0.001). The incidence of adverse reactions in the observation group was 7.50%, markedly lower than the 25.00% observed in the control group (P < 0.05). Conclusion: Moxifloxacin demonstrates better clinical efficacy and safety in the treatment of elderly patients with CAP, making it a valuable option for clinical application. However, the choice of medication should still consider individual patient conditions comprehensively.
References
Zhang Z, Chen J, Li Y, et al., 2019, Application of Combined Serum and Bronchoalveolar Lavage Fluid Inflammatory Factor Detection in the Diagnosis and Treatment Evaluation of Pathogens in Community-Acquired Pneumonia. Hebei Medical Journal, 41(19): 2997–2999 + 3003.
Wang Z, Zhao D, 2020, Analysis of the Efficacy and Safety of Tanreqing Combined with Levofloxacin Hydrochloride in Community-Acquired Pneumonia. World Journal of Traditional Chinese Medicine, 2020(12): 1774–1777.
Zhou W, Rao J, Chen L, 2019, Clinical Observation of Shufeng Jiedu Capsules Combined with Moxifloxacin in the Treatment of Community-Acquired Pneumonia. Chinese Journal of Emergency Traditional Chinese Medicine, 28(8): 1460–1462.
Wang R, Zheng X, Fei Y, 2019, Clinical Observation of the Efficacy of Moxifloxacin in the Treatment of Elderly Patients with Community-Acquired Pneumonia. Journal of Clinical Rational Drug Use, 12(35): 43–44.
Chinese Thoracic Society, Chinese Medical Association, 2016, Guidelines for the Diagnosis and Treatment of Adult Community-Acquired Pneumonia in China (2016 Edition). Chinese Journal of Tuberculosis and Respiratory Diseases, 39(4): 253–279.
Huang W, 2020, Current Status of the Diagnosis and Treatment of Community-Acquired Pneumonia. Medical Clinical Research, 37(2): 161–163.
Yao D, Deng Y, Liu Z, et al., 2019, Correlation Between Sputum Microbiota Characteristics and Eosinophil Levels in Community-Acquired Pneumonia. Chinese Journal of Microecology, 31(4): 413–418.
Qu Z, Cao Y, Zhang H, et al., 2019, Observation of the Efficacy of a Self-Prepared Qingfei Huatan Decoction Combined with Moxifloxacin in Treating Community-Acquired Pneumonia of Cold Exterior and Hot Interior Type. Beijing Journal of Traditional Chinese Medicine, 38(4): 328–331.
Nian Y, Lv X, 2019, Effect of Meropenem Combined with Moxifloxacin on Patients with Chronic Obstructive Pulmonary Disease Complicated with Infectious Pneumonia. Practical Journal of Cardiac Cerebral Pneumonic and Vascular Disease, 27(3): 87–90.
Lu Y, Shao D, Sun Y, et al., 2020, Efficacy of Lianhua Qingwen Capsules Combined with Levofloxacin in the Treatment of Community-Acquired Pneumonia and Its Effects on LCQ Scores and Inflammatory Factors. Journal of Difficult and Complicated Cases, 19(11): 1152–1156.